BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures.
[News Source]
[News Source]
Blogsphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg
RSS feed for comments on this post
Resources
Subscribe 
Pages
Admin
Pages
Admin
Recent Comments
Categories
Archives
